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Abstract Cardiovascular (CV) disease is the leading cause
of morbidity and mortality for women all over the world.
The role and weight of risk factors in relation to gender are
not completely clarified as well as their treatment. Patho-
physiology of hypertension in woman presents different
aspects in relation to phase of life, with an impact on
treatment. The only certainties that we have nowadays
regarding hypertension therapy in women are really few
and may be summarized in: how to treat or, better, what not
to use in hypertension in pregnancy and how to treat acute
severe hypertension in pregnancy. We have some certain-
ties also on treatment of hypertension associated to some
women’s comorbidities. Considering guidelines and ana-
lyzing what happens in the real world, we report in this
review that women have similar major CV risk factors of
men, although a minor CV global risk. However, there are
some data that suggest that hypertension and diabetes are
more important risk factors in women than in men. Blood
pressure reduction and benefit by treatment appear similar
in women and men, suggesting that we should aim for
similar target of blood pressure, although the lower global
risk profile should imply different target. Theoretically,
recommended drugs are similar in women and men, but in
women we must take in account CV risk profile, comor-
bidity, side effects, and reproductive health. Finally, reg-
istries and observational studies show that fewer women
reach the target values of blood pressure and that women
receive more frequently prescription of ‘‘other’’ classes of
drugs than those recommended by guidelines, even after
normalization by age and comorbidities.
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1 Introduction
Cardiovascular (CV) disease is the leading cause of mor-
bidity and mortality for women all over the world. The role
and weight of risk factors in relation to gender are not
completely clarified as well as their treatment, except for
lifestyle’s modification which is the common soil either in
men as well as in women for first pass therapy of all dis-
eases. Guidelines do not clearly identify differences in
relation to gender, but the therapeutic response depends on
the interaction between genes, environment and culture;
therefore, it is important to define the concepts of sex and
gender. Sex includes everything related to biology (genes,
hormones, etc.), while the concept of gender, brought to the
biomedical and human sciences, includes cultural, envi-
ronmental and social influences [1]. In particular, patho-
physiology of hypertension in women presents different
aspects in relation to phases of life, with an obvious impact
on treatment. This does not happen in men, who never-
theless have always been enrolled in a much larger number
in clinical trials.
2 Do We Have Certainties on Pharmacological
Therapy in Women?
The only certainties that we have nowadays regarding
hypertension therapy in women are really few and may be
summarized in: how to treat or, better, what not to use in
hypertension during pregnancy and how to treat acute
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(severe) hypertension in pregnancy. These issues are dis-
cussed in other chapters of the present volume. We have
some certainties also on treatment of hypertension associ-
ated to some women’s comorbidities as thiazide use and
risk for osteoporotic fractures among hypertensive patients.
For example, the Swedish primary Care Cardiovascular
Data-base (SPCCD) clearly demonstrated their efficacy on
fractures during 7 years of follow-up [2]. Finally, we know
that isolated systolic hypertension is more frequent in
elderly women and that its treatment is often associated
with orthostatic hypotension, caused or exacerbated by a
list of well-known drugs (Table 1).
There are otherwise only general recommendations
deriving from observations in literature [3] and different
guidelines [4, 5] (Table 2).
There are also general recommendations deriving from
different guidelines:
• major risk factors for cardiovascular complications in
women and men are similar.
It is usually reported that major risk factors for cardio-
vascular complications in women and men are similar and
if we use the algorithms, like the SCORE Chart [5] or
Framingham index [6], we usually consider the same risk
factors: smoking, age, blood pressure, cholesterol. So
major risk factors are the same. Although if we observe
either the score and the index in relation to risk factors and
sex, we clearly derive that the overall cardiovascular risk in
women is lower. However, there are some data that suggest
that blood pressure as a risk factor is more important for
cardiovascular events in women than in men, but in men
atherosclerotic process is more important. Diabetes of
course confers high risk for cardiovascular complications,
but it confers a greater risk in women than in men. As we
mentioned, there are lower global cardiovascular risk
profile in women and we know that the reproductive
history complications during pregnancy is relevant, and
obviously in women. So major risk factors are similar, but
they are not the same.
There are otherwise only commonly quoted general
recommendations deriving from different guidelines:
• similar blood pressure reduction by treatment are
important either in women as in men
• similar benefits are obtained by treatment in women
and men.
It is reported that similar blood pressure reduction by
treatment should be used in women and men, and it is
stated that similar benefit by treatment is apparent in
women and men and thus we should have similar target
blood pressure in women and in men if the risk is the same
and the benefit is the same. First of all, there are very few
studies on outcome in women treated for hypertension.
Many studies include women and the trend is positive but
still the inference is that we study effects on the population
and we see that there is an interaction between women and
men and outcome, and very few showed effects of anti-
hypertensive treatment in women alone [7]. So, the
knowledge is insufficient, at least in our opinion.
We can have some help by using meta-analysis, such as
that one by Turnbull et al. [8], published almost 10 years
ago, where, in the ‘‘The blood pressure lowering treatment
trialists’ collaboration’’ they put together the effects of
hypertensive treatment in women and men analyzing
patient’s data from 31 randomized controlled trials on
blood pressure lowering agents including (but not limited
to) hypertension. The total number of patients was 87,349
women and 103,268 men, in trials published in 1995 or
later. Proportion of women was 47 (range 11–67)%, mean
age was 63 and 62 years in women and men, respectively
and mean follow up was 2.6–8.2 years. If we use this kind
of meta-analysis, we can see that coronary heart disease is
Table 1 Drugs associated with orthostatic hypotension
Examples of drugs that can cause or exacerbate orthostatic hypotension in women
Alpha-blockers: doxazosina (eg.)
Antidepressant drugs: selective serotonin receptor reuptake inhibitors, trazodone, monoamine oxidase, inhibitors, tricyclic antidepressants
Antihypertensive drugs: sympathetic blockers (eg.)
Antiparkinsonism drugs: levodopa, pramipexole, ropinirole (egs.)
Antipsychotic drugs: olanzapine, risperidone (egs.)
Beta-blocker drugs: propranolol (eg.)
Diuretic drugs: hydrochlorothiazide, furosemide (egs.)
Muscle relaxant drugs: tizanidine (eg.)
Narcotic analgesic drugs: morphine (eg.)
Sedatives/hypnotic drugs: temazepam (eg.)
Vasodilator drugs: hydralazine, nitroglycerin, calcium channel blockers (egs.)
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more prevalent in men than in women, again supporting
that atherosclerosis is more important in men, and major
cardiovascular disease and mortality again is higher in men
than in women. In this analysis they compared different
drug classes, drug classes vs placebo, and also different
doses of the same drugs. And if we compare differences in
blood pressure reduction between women and men in the
same studies by enlarge blood pressure, it seems to be
reduced to similar degree both in women and as in men. So,
this may suggest that blood pressure lowering treatment
reduces blood pressure to similar degree in women and
men. Looking afterwards to composite outcomes (major
cardiovascular events) by comparing ACE inhibitors vs
placebo, male and female, calcium antagonists vs placebo,
and more vs less intensive treatment, benefits seems to be
similar between women and men for all these three com-
parisons. Looking moreover for ARBs vs. placebo or for
comparisons between ACE inhibitors, calcium blockers vs
beta-blockers, or ACE inhibitors vs calcium antagonists,
again blood pressure reduction by enlarge seems to be
similar as well as outcomes in women and men. So, we
could derive that there is theoretically support to suggest
that blood pressure reduction by treatment is similar in
women and men. The benefit in terms of relative risk
reduction seems to be similar in women and men and
therefore also same target blood pressure should be
obtained. However, the total risk is lower in women, then
the doubt remains that it would be logical for women to
have higher blood pressure target than men.
There are otherwise only commonly quoted general
recommendations deriving from different guidelines:
• similar drug classes should be recommended for the
treatment of hypertension in women and men.
The very well done meta-analysis by Turnbull et al. [8]
would lead us to assert that we should use similar drugs
classes with evidence derived from large clinical trials,
both in women and men. There are nevertheless side
effects much more common in women. First of all, from
airways by Ace inhibitors and we know moreover that
asthma is more frequent in young women and chronic
obstructive pulmonary disease (COPD) in the elderly. This
allow us to say that ACE inhibitors are not preferred in
women with COPD or asthma, because of the risk of side
effects. Swollen ankles from calcium antagonists are more
common in women than in men, that maybe an argument to
favor diuretic therapy in women, although diuretics gen-
erally are not able to solve the problem. Sometimes alpha-
blockers also, which have a strong indication in hyper-
tensive men with prostatic problems, induce swollen ankles
in women, but the association with diuretics may cause
severe hypotension. Another gender related difference with
impact on pharmacological treatment is the prevalence in
women of comorbidities, such as autoimmune diseases.
Women attempt primary care more often for inflammatory
disease and pain, they consume more steroids and non-
steroid anti-inflammatory drugs, which may counteract
anti-hypertensive therapy because of possible side-effects
on the.
Finally, postmenopausal status is associated with a 60%
increased risk of metabolic syndrome (MS) and another
cause of hypertension in post-menopause is obesity [9].
Hypertension associated with MS has a more severe car-
diovascular risk and the response to therapy is less favor-
able than the isolated form of hypertension. This effect is
due to MS-induced systemic endothelial dysfunction and
chronic subclinical inflammation, factors that are recog-
nized as powerful risk factors for cardiac and cerebrovas-
cular events [10].
Data from our group demonstrated many years ago that
the number of antihypertensive drugs used to maintain
blood pressure in the normal range (\ 140/\ 90 mmHg)
was on average higher in hypertensive women with MS
(4.5 ± 1) versus hypertensive women without MS
(3.5 ± 1; P\ 0.05). The principal treatment was ACE
inhibitors and ARBs. In particular, hypertensive women
with MS, antihypertensive the treatment produced a more
modest improvement of both endothelial dysfunction and
subclinical inflammation comparing to the other group
[11]. In the real word nevertheless, these commonly quoted
general recommendations deriving from different guideli-
nes do not appear totally confirmed.
Data from the International Survey Evaluating
Microalbuminuria Routinely by Cardiologists in patients
with Hypertension (I-SEARCH) [12] report gender dis-
parities in antihypertensive drug usage and blood pressure
(BP) control. The survey included 18,017 patients with
hypertension and the study was conducted between
September 2005 and March 2006 in 26 countries, collect-
ing data on patient demographics, cardiovascular disease
and risk factors, blood pressure, and cardiovascular drug
treatment were collected. Mean systolic blood pressure
Table 2 Commonly quoted
general recommendations
deriving from different
guidelines
Major risk factors for cardiovascular complications in women and men are similar
Similar blood pressure reduction by treatment are important either in women as in men
Similar target blood pressure values are valid for women and men
Similar drug classes should be recommended for the treatment of hypertension in women and men
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(SBP) was 2.1 mmHg higher in women (150.6?/-
0.35 mmHg, n = 8357/18,017) than in men (148.5?/-
0.35 mmHg; P\ 0.0001, n = 9526/18,017), whereas no
difference in diastolic BP was seen (88.2?/- 0.20 vs
88?/- 0.20 mmHg; P = 0.198). Gender differences in
SBP were more pronounced in diabetic as compared with
non-diabetic patients (3.5 vs 1.7 mmHg, n = 4272 vs
n = 13 611; P\ 0.0001) and became evident at age of
55 years old. Overall BP-control rate was 33.6% in men
and 30.6% in women (P\ 0.0001) and was lower in dia-
betic as compared with non-diabetic patients. In all, 30% of
patients used one, 40% used two and 30% used[ or = 3
drugs without gender differences. Response rates to dif-
ferent drug regimens appeared to be similar. However,
women received more frequently thiazides and beta-
blockers, and less frequently ACE-inhibitors as
monotherapy.
3 Conclusions
Women have similar major CV risk factors (albeit, lower
global CV risk) as men, but blood pressure and diabetes
may have greater impact; we should consider also repro-
ductive history in women. Blood pressure reductions and
benefits by treatment appear similar in women and men in
relative terms, suggesting that we should aim for similar
target pressure, although the lower global risk profile
should imply different target. Recommended drugs should
be similar in women and men, but we must take in account
CV risk profile, comorbidity, side effects, and reproductive
health. However, registries and observational studies show
that fewer women reach the target values of pressure and
that women are more frequently prescribed ‘‘other’’ classes
of drugs, even after normalization by age and comorbidi-
ties. There is room from improvement and this will likely
provide major clinical benefit, equal for men and women.
Compliance with Ethical Standards
Conflict of interest On behalf of all authors, the corresponding
author states that there is no conflict of interest.
Ethical approval This article does not contain any studies with
human participants or animals performed by any of the authors.
References
1. Legato MJ, editor. Principle of gender-specific medicine—gender
in the genomic era. 3rd ed. New York: Elsevier; 2017.
2. Bokrantz T, Ljungman C, Kahan T, Schioler L, et al. Thiazide
diuretics and fracture-risk among hypertensive patients. Results
from the Swedish Primary Care Cardiovascular Database
(SPCCD). J Hypertens. 2015;33(e Suppl 1):e94–5.
3. Muiesan ML, Salvetti M, Rosei CA, Paini A. Gender differences
in antihypertensive treatment: myths or legends? High Blood
Press Cardiovasc Prev. 2016;23(2):105–13.
4. 2013 ESH/ESC Guidelines for the management of arterial
hypertension: the Task Force for the management of arterial
hypertension of the European Society of Hypertension (ESH) and
of the European Society of Cardiology (ESC). Eur Heart J.
2013;28:2159–219.
5. European Guidelines on cardiovascular disease prevention in
clinical practice: The Sixth Joint Task Force of the European
Society of Cardiology and Other Societies on Cardiovascular
Disease Prevention in Clinical Practice. Eur Heart J.
2016;37(29):2315–81.
6. Mahmood SS, Levy D, Vasan R, Wang TJ. The Framingham
Heart Study and the epidemiology of cardiovascular disease: a
historical perspective. Lancet. 2014;383(9921):999–1008.
7. Ljungman C, Mortensen L, Kahan T, Manhem K. Treatment of
mild to moderate hypertension by gender perspective: a system-
atic review. J Womens Health (Larchmt). 2009;18(7):1049–62.
8. Turnbull F, Woodward M, Neal B, Barzi F, et al. Do men and
women respond differently to blood pressure-lowering treatment?
Results of prospectively designed overviews of randomized trials.
Eur Heart J. 2008;29(21):2669–80.
9. Roka R, Michimi A, Macy G. Associations between hypertension
and body mass index and waist circumference in U.S. adults: a
comparative analysis by gender. High Blood Press Cardiovasc
Prev. 2015;22(3):265–73.
10. Leuzzi C, Modena MG. Hypertension in postmenopausal women.
Pathophysiology and treatment. High Blood Pressure Cardiov
Prev. 2011;18(1):13–8.
11. Rossi R, Nuzzo AC, Origliani G, Modena MG. Metabolic syn-
drome affects cardiovascular risk profile as response to treatment
in hypertensive postmenopausal women. Hypertension.
2008;52(2):865–72.
12. Thoenes M, Neuberger HR, Volpe M, Khan BV. Antihyperten-
sive drug therapy and blood pressure control in men and women:
an international perspective. J Hum Hypertens.
2010;24(5):336–44.
E. Lodi et al.
Author's personal copy
